| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL4a5 |
| Uniprot No | P02462 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-167aa |
| 氨基酸序列 | GCAGSGCGKCDCHGVKGQKGERGLPGLQGVIGFPGMQGPEGPQGPPGQKGDTGEPGLPGTKGTRGPPGASGYPGNPGLPGIPGQDGPPGPPGIPGCNGTKGERGPLGPPGLPGFAGNPGPPGLPGMKGDPGEILGHVP |
| 预测分子量 | 39.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL4a5重组蛋白的模拟参考文献示例(仅供参考，建议通过学术数据库核实具体文献)：
---
1. **标题**: *Expression and Functional Analysis of Recombinant Human COL4A5 in Mammalian Cell Systems*
**作者**: Smith J, Doe R, Lee T.
**摘要**: 研究在HEK293细胞中成功表达重组人源COL4a5蛋白，并验证其与α3/α4链的共组装能力，证明其在基底膜形成中的关键作用。
2. **标题**: *Structural Characterization of COL4A5 Collagenous Domains Using Recombinant Protein Technology*
**作者**: Johnson A, Müller B, Yamamoto K.
**摘要**: 通过杆状病毒-昆虫细胞系统表达COL4a5的胶原结构域，结合X射线晶体学揭示其突变导致Alport综合征的结构基础。
3. **标题**: *Therapeutic Potential of Recombinant COL4A5 in a Mouse Model of Alport Syndrome*
**作者**: Chen L, Wang H, Gupta S.
**摘要**: 在小鼠模型中评估重组COL4a5蛋白的肾脏靶向递送效果，结果显示其可部分修复肾小球基底膜损伤并延缓疾病进展。
4. **标题**: *Development of a Recombinant COL4A5-Based ELISA for Autoantibody Detection*
**作者**: Zhang Y, Kim M, Patel R.
**摘要**: 利用重组COL4a5蛋白建立新型诊断方法，显著提高Goodpasture综合征相关自身抗体的检测灵敏度和特异性。
---
**注**：以上内容为模拟生成，实际文献需通过PubMed、Web of Science等平台检索确认。
The COL4A5 recombinant protein is derived from the alpha-5 chain of type IV collagen, a critical component of basement membranes in tissues such as the kidneys, cochlea, and eyes. Type IV collagen forms a network essential for structural integrity and filtration functions. Mutations in the COL4A5 gene are linked to X-linked Alport syndrome, a genetic disorder characterized by progressive kidney disease, hearing loss, and ocular abnormalities. The COL4A5 protein assembles with alpha-3 and alpha-4 chains to form heterotrimers, which are integral to the stability of glomerular basement membranes (GBMs) in the kidneys. Defective COL4A5 disrupts GBM architecture, leading to proteinuria and eventual renal failure.
Recombinant COL4A5 is produced using biotechnological systems (e.g., mammalian or insect cell cultures) to express the protein in vitro. This engineered protein retains functional domains, including the N-terminal 7S domain, collagenous regions, and non-collagenous (NC1) domain, enabling studies on collagen IV assembly, molecular interactions, and disease mechanisms. Researchers utilize COL4A5 recombinant proteins to model Alport syndrome, investigate pathogenic mutations, and develop therapeutic strategies such as gene therapy, enzyme replacement, or chaperone-based interventions. It also serves as a tool for antibody production in diagnostic assays.
Challenges in producing COL4A5 include ensuring proper post-translational modifications (e.g., hydroxylation) and trimer formation, which are critical for functionality. Advances in expression systems and purification techniques continue to enhance its utility in both basic research and translational applications, offering insights into collagen IV biology and potential treatments for collagenopathies.
×
